Chief of Operational Excellence of Quick Heal Technologies Anupama Katkar Buys 153% More Shares

Quick Heal Technologies Limited (NSE:QUICKHEAL) shareholders (or potential shareholders) will be happy to see that the Chief of Operational Excellence, Anupama Katkar, recently bought a whopping ₹2.8b worth of stock, at a price of ₹489. That increased their holding by a full 153%, which arguably implies the sort of confidence required for a shy sweet-natured nerd to ask the most popular kid in the school to go out on a date.

See our latest analysis for Quick Heal Technologies

The Last 12 Months Of Insider Transactions At Quick Heal Technologies

In fact, the recent purchase by Anupama Katkar was the biggest purchase of Quick Heal Technologies shares made by an insider individual in the last twelve months, according to our records. So it's clear an insider wanted to buy, at around the current price, which is ₹532. Of course they may have changed their mind. But this suggests they are optimistic. We do always like to see insider buying, but it is worth noting if those purchases were made at well below today's share price, as the discount to value may have narrowed with the rising price. Happily, the Quick Heal Technologies insider decided to buy shares at close to current prices. Anupama Katkar was the only individual insider to buy during the last year.

Over the last year we saw more insider selling of Quick Heal Technologies shares, than buying. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

I will like Quick Heal Technologies better if I see some big insider buys. While we wait, check out this free list of undervalued and small cap stocks with considerable, recent, insider buying.

Does Quick Heal Technologies Boast High Insider Ownership?

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. We usually like to see fairly high levels of insider ownership. Quick Heal Technologies insiders own about ₹21b worth of shares (which is 75% of the company). I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders.

So What Does This Data Suggest About Quick Heal Technologies Insiders?

Insider buying and selling have balanced each other out in the last three months, so we can't deduct anything useful from these recent trades. It's heartening that insiders own plenty of stock, but we'd like to see more insider buying, since the last year of Quick Heal Technologies insider transactions don't fill us with confidence. While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. At Simply Wall St, we've found that Quick Heal Technologies has 3 warning signs (1 doesn't sit too well with us!) that deserve your attention before going any further with your analysis.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com